Submit Deal

OCULIS

Summary

Oculis is a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 235 M

Avg. Deal Size£ 118 M

Market Context

Senior Management

Riad Sherif
CEO
Sylvia Cheung
CFO
Louie-Anne Gauthier
VP Strategic Marketing

Sort

citigate dewe rogerson

HQ - London

pr advisors (1)

1 Shared Deal

1 For

£ 41 M

Total Value

white & case

HQ - New York

legal advisors (1)

1 Shared Deal

1 Opposite

£ 41 M

Total Value

consilium strategic communications

pr advisors (1)

1 Shared Deal

1 For

£ 195 M

Total Value

bank of america

HQ - Charlotte

financial advisors (2)

2 Shared Deals

1 For | 1 Opposite

£ 389 M

Total Value

cooley

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 For

£ 195 M

Total Value

vischer

legal advisors (1)

1 Shared Deal

1 For

£ 195 M

Total Value

leerink partners

financial advisors (2)

2 Shared Deals

1 For | 1 Opposite

£ 389 M

Total Value

pricewaterhousecoopers

HQ - London

accounting advisors (1)

1 Shared Deal

1 For

£ 195 M

Total Value

credit suisse

HQ - Zürich

financial advisors (1)

1 Shared Deal

1 Opposite

£ 195 M

Total Value

stibbe

legal advisors (1)

1 Shared Deal

1 Opposite

£ 195 M

Total Value

van lanschot kempen

financial advisors (1)

1 Shared Deal

1 Opposite

£ 195 M

Total Value

maples group

HQ - Cayman Islands, Cayman Islands

legal advisors (1)

1 Shared Deal

1 Opposite

£ 195 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy